Daily Sepsis Research Analysis
Analyzed 41 papers and selected 3 impactful papers.
Summary
Three impactful sepsis studies span mechanistic discovery, diagnostics, and data validity. A Cell Death & Differentiation paper reveals a neutrophil-intrinsic EGFR–MAPK14–CEBPβ–PGLYRP1–TREM-1 axis driving NETosis and mortality in murine sepsis, suggesting a druggable pathway. A meta-analysis plus cohort study identifies Annexin A3 as a promising predictive biomarker outperforming PCT and IL-6, while a registry validation study shows poor PPV of ICD-10 neonatal sepsis/meningitis codes, urging microbiologic confirmation and consensus definitions.
Research Themes
- Neutrophil-driven immunopathology and NETosis regulation in sepsis
- Biomarker discovery and validation for sepsis diagnosis and risk stratification
- Data quality, coding validity, and surveillance accuracy in neonatal sepsis
Selected Articles
1. EGFR orchestrates neutrophil activation and NETosis via CEBPβ-dependent PGLYRP1 induction.
This mechanistic study shows that neutrophil-intrinsic EGFR signaling drives NETosis through a MAPK14-assisted activation of CEBPβ, which induces PGLYRP1 to amplify TREM-1 signaling. Neutrophil-specific EGFR deletion reduces NETs, cytokine storm, and mortality in murine polymicrobial sepsis; rescue experiments confirm pathway centrality.
Impact: Defines a previously unrecognized EGFR–PGLYRP1–TREM-1 circuit linking receptor signaling to pathological NETosis, offering a tractable therapeutic target. Integrates human sepsis correlations with rigorous in vivo genetic and rescue approaches.
Clinical Implications: Supports exploration of EGFR pathway modulation (or downstream PGLYRP1/TREM-1 blockade) to attenuate neutrophil-driven immunopathology in sepsis. May inform biomarker-guided stratification of patients with elevated neutrophil EGFR.
Key Findings
- EGFR expression is elevated in neutrophils from sepsis patients and correlates with disease severity.
- Neutrophil-specific EGFR deletion improves survival and reduces cytokine storm, tissue injury, and NET formation in polymicrobial sepsis.
- EGFR recruits MAPK14 to phosphorylate CEBPβ, promoting nuclear localization and transcriptional activation of PGLYRP1.
- PGLYRP1 amplifies NET release via autocrine TREM-1 engagement, creating a feed-forward inflammatory loop.
- Recombinant PGLYRP1 or forced CEBPβ overexpression reverses the protection conferred by EGFR deficiency.
Methodological Strengths
- Integration of human patient data with neutrophil-specific genetic models in mice
- Mechanistic dissection with phosphorylation, transcriptional, and rescue experiments
Limitations
- Preclinical mouse models may not fully recapitulate human sepsis heterogeneity
- Safety and off-target effects of EGFR or PGLYRP1/TREM-1 modulation in infection require evaluation
Future Directions: Test pharmacologic EGFR, PGLYRP1, or TREM-1 inhibitors in diverse sepsis models and assess predictive biomarkers (neutrophil EGFR/CEBPβ/PGLYRP1) for patient stratification.
Excessive neutrophil activation and neutrophil extracellular trap (NET) release drive systemic inflammation and organ injury in sepsis, yet the upstream regulatory pathways remain incompletely defined. Here, we identify epidermal growth factor receptor (EGFR) as a critical neutrophil-intrinsic regulator of NETosis. EGFR expression was markedly elevated in neutrophils from patients with sepsis and correlated with disease severity. Neutrophil-specific EGFR deletion in mice improved survival after polymicrobial sepsis by reducing cytokine storm, tissue injury, and N
2. Aldehyde Dehydrogenase-2 Alleviates Septic Myocardial Injury by Inhibiting Caspase-11-Mediated Noncanonical Pyroptosis.
In CLP-induced sepsis, pharmacologic activation of ALDH2 (Alda-1) and ALDH2 overexpression protect against myocardial injury. Mechanistically, ALDH2 suppresses caspase-11–dependent noncanonical pyroptosis and interacts with HMGB1, RAGE, and GSDMD.
Impact: Links a metabolically oriented enzyme (ALDH2) to caspase-11–mediated pyroptosis in septic cardiomyopathy and demonstrates therapeutic benefit with an agonist.
Clinical Implications: Suggests ALDH2 activation as a potential cardioprotective strategy in sepsis. Encourages translation of Alda-1 or related modulators toward septic cardiomyopathy after safety and efficacy studies.
Key Findings
- Alda-1 significantly attenuated CLP-induced cardiac dysfunction and histologic/ultrastructural myocardial injury in mice.
- ALDH2 overexpression reduced LPS-induced cardiomyocyte injury markers (CK-MB, LDH) and improved cell viability.
- ALDH2 upregulation decreased caspase-11, HMGB1, and RAGE expression, implicating noncanonical pyroptosis suppression.
- Co-immunoprecipitation indicates ALDH2 directly interacts with HMGB1, RAGE, and GSDMD.
Methodological Strengths
- In vivo CLP model with functional echocardiography and ultrastructural TEM assessments
- Convergent in vitro mechanistic assays including overexpression and co-immunoprecipitation
Limitations
- Primarily preclinical; no human validation of ALDH2 pathway in septic cardiomyopathy
- Potential off-target effects of Alda-1 and dosing strategies not fully characterized
Future Directions: Validate ALDH2 pathway activity in human SICM, optimize dosing and timing of Alda-1, and test combination with anti-inflammatory or anti-pyroptotic agents.
PURPOSE: The purpose of this study is to investigate the role of aldehyde dehydrogenase-2 (ALDH2) in septic myocardial injury, focusing on noncanonical pyroptosis. METHODS: In vivo, C57BL/6J mice were divided into five groups: Sham, cecal ligation and puncture (CLP), CLP + Alda-1 (ALDH2 agonist), Sham + dimethyl sulfoxide (DMSO, solvent control), and CLP + DMSO. Cardiac function and histological/ultrastructural changes were assessed via echocardiography, hematoxylin-eosin (HE) staining, and transmission electron microscopy (TEM). Tumor necrosis factor- RESULTS: In vivo, Alda-1 significantly attenuated CLP-induced cardiac dysfunction and reduced myocardial histological damage and ultrastructural impairment. In vitro, ALDH2 overexpression lowered LPS-induced H9C2 cell viability, CK-MB, and LDH release. Upregulating ALDH2 significantly reduced caspase-11, HMGB1, and RAGE expression. CO-IP showed ALDH2 interacted with HMGB1, RAGE, and GSDMD. CONCLUSION: ALDH2 protects the myocardium from septic injury by inhibiting caspase-11-mediated noncanonical pyroptosis, possibly via direct interactions with GSDMD, HMGB1, and RAGE.
3. Assessment of Annexin A3 as a Potential Biomarker for Sepsis in Critically Ill Patients: A Meta-analysis and Retrospective Cohort Study.
Aggregating transcriptomic datasets and a 153-patient cohort, ANXA3 is elevated in sepsis and shows strong predictive performance (AUC 0.815), outperforming PCT, IL-6, and SOFA. Higher plasma ANXA3 correlates with worse 28-day survival in critically ill patients overall.
Impact: Identifies a biomarker with superior discriminatory capacity to commonly used indices, supporting its potential role in early sepsis prediction.
Clinical Implications: ANXA3 could augment early sepsis identification and triage in ICUs. Implementation will require standardized assays, prospective validation, and assessment of additive value to clinical scores.
Key Findings
- Meta-analysis of GEO/ArrayExpress (3241 sepsis, 1088 controls) shows significantly higher ANXA3 mRNA in sepsis (SMD 2.01; P<0.001).
- Plasma ANXA3 at admission predicts incident sepsis in critically ill patients (OR 2.41; P<0.001).
- ANXA3 predictive AUC 0.815 exceeds PCT (0.673), IL-6 (0.672), and SOFA (0.668).
- Higher ANXA3 associates with poorer 28-day survival in critically ill patients (HR 2.16; P<0.05), but not within the sepsis subgroup.
Methodological Strengths
- Combined evidence from large-scale transcriptomic meta-analysis and an independent clinical cohort
- Head-to-head comparison against established biomarkers and SOFA with AUC reporting
Limitations
- Retrospective single-center cohort with modest sample size for plasma validation
- Heterogeneity in public datasets and lack of prospective, multicenter validation
Future Directions: Prospective multicenter studies to validate ANXA3 assays, assess incremental value over clinical scores, and define decision thresholds and kinetics.
BackgroundCurrent research indicated the comprehensive investigation of Annexin A3 (ANXA3) in sepsis patients remain uncertain. The aim of this research is to investigate the potential of ANXA3 as a biomarker for prediction of sepsis.MethodsWe performed a meta-analysis utilizing public datasets from Gene Expression Omnibus (GEO) and Array Express database to summarize and evaluate the expression of ANXA3 in sepsis patients. Then, we conducted a retrospective study to explore the role of plasma ANXA3 in 153 critically ill patients. Furthermore, the predictive ability of ANXA3, procalcitonin (PCT), interleukin-6 (IL-6) and Sequential Organ Failure Assessment (SOFA) score for the occurrence of sepsis were evaluated using the Area Under the Curve (AUC).ResultsTotally, the meta-analysis including 3241 sepsis and 1088 controls indicated sepsis patients were with markedly higher levels of ANXA3 mRNA expression (SMD = 2.01(1.54-2.48); P < 0.001). Meanwhile, sepsis deaths (n = 552) were with limited higher expression of ANXA3 mRNA than sepsis survivors (n = 2004) (SMD = 0.14(0.04-0.24); P < 0.01). Furthermore, our results indicated increased plasma ANXA3 on admission were significantly associated with the incidence of sepsis in critically ill patients (OR = 2.41(1.75-3.32), P < 0.001). As a predictive biomarker, plasma ANXA3 resulted in a better AUC 0.815(0.745-0.886) than PCT (0.673(0.584-0.761)) and IL-6 (0.672(0.585-0.759)) and SOFA score (0.668(0.577-0.759)). Additionally, patients with higher plasma ANXA3 had a poorer overall 28-day survival in critically ill patients (HR = 2.16(1.09-4.28); P < 0.05), but not for sepsis patients (HR = 1.63(0.65-4.06); P > 0.05).ConclusionsOur study indicated increased ANXA3 obtained a good predictive ability for sepsis. Meanwhile, plasma ANXA3 was associated with mortality of critically ill patients, but not sepsis patients. The use of ANXA3 as a biomarker in sepsis patients require further evaluation in larger studies.